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ABSTRACT
Between January 1994 and February 1998, 32,limited-stage small-cell lung cancer patients were treated with
concurrent chemoradiotherapy. Follow-up time ranged from 4 to 34 months, (median 14 months). Complete
regression was obtained in 22 of the 30 patients, who received at least four courses of EP chemotherapy and a
tumour dose of 50 Gy or more. In all, 2-year actuarial disease-free survival was 21%. Brain metastases occurred
in 8 (36.4%) patients with CR, in 5/7 (71.4%) patients without prophylactic cranial irradiation (PCI) and in 3/15
(20%) patients after PCI. The survival rate was lower in patients with PCI, in Whom chest irradiation was started
later than one month from the beginning of course 1 of EP chemotherapy. We have suggested a modification of
the treatment protocol.
Small-cell lung cancer (SCLC) is the second
most frequent histologic subtype, accounting
for 25% of all lung tumours. About one third of
cases is diagnosed at a stage of the disease
limited to one side of the chest. SCLC is highly
sensitive to chemotherapy, which can lead to a
response rate of 70-80% and, in patients with
limited-stage disease, achieve even up to 50%
complete remissions. Nevertheless, most
patients experience a relapse. Despite
improvement of the median survival obtained
with multidrug chemotherapy the prognosis
remains poor. Only about 10% limited - stage
patients are long-term survivors (Sandler et aI.,
1993; Coy et al., 1993).
To improve the results of treatment results
the following main subjects are investigated in
clinical trials: (a) optimum number of
chemotherapy courses and the value of
maintenance therapy, (b) application of
alternating chemotherapy regimens with non-
cross resistant drugs, (c) weekly versus
monthly regimen, (d) increase in radiation dose
and in high-dose chemotherapy with bone
marrow or peripheral blood progenitor cell
transplantation, (e) addition of new drugs and
use of new regimens, (f) combined chemo- and
radiotherapy and optimum timing of chest
irradiation (Elias, 1998; Thatcher et aI., 1998;
Tomeczko et aI., 1997; Brugger et aI., 1998).
Two meta-analyses have shown a small but
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significant improvement in survival for patients
treated with chemotherapy plus radiation
versus chemotherapy alone. Especially
interesting are updated results of CALGB
Study 8083. In a group of 399 patients, with a
follow-up of 10 years, modes which included
thoracic radiation therapy remained superior to
chemotherapy alone. Addition of thoracic
radiation therapy to combination chemotherapy
improves complete response rates and
survival, with increased, but acceptable,
toxicity (Perry et aI., 1998; Albain et aI., 1990;
Bonomi,1998).
Since January 1994, at the Department
of Radiation Oncology, Centre of Oncology
in Krak6w (COK) phase II of the clinical trial
for the assessment of effectiveness and
toxicity of concurrent chemoradiotherapy has
been carried out.
The aim of this paper is to present our results
in the pilot group of patients with limited-stage
SCLC.
MATERIAL AND METHODS
Between January 1994 and February, 32
patients with a limited-stage SCLC were
treated with concurrent chemoradiotherapy.
The inclusion criteria were as follows:
- histologically proven SCLC limited to one
side of the chest, Le.: T1-4, herein with
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positive cytology of pleural liquid, N1-3,
herein with metastases to opposite hilar
lymph nodes, but with exclusion of
patients with metastases to opposite
supraclavicular lymph nodes,
• performance state, ~ 60% (Karnofsky
scale), adequate respiratory functions
(FEV1 ~ 1000 ml), normal renal and blood
tests.
Obligatory staging included bronchoscopy with
biopsy, chest X-ray (PA and lateral),
spirometry, trepanobiopsy, bone scan,
abdominal USG, chest and brain computed
tomography (CT), and biochemical profile.
Chemotherapy consisted of PE regimen
(cisplatin 30 mg/m2 day 1, 2, 3 and etoposide
120 mg/m2 day 1, 3, 5) started immediately
after staging work-up was completed. Five
courses of EP regimen were applied with three
- week intervals, with concurrent chest
irradiation. Radiotherapy was introduced 2 - 16
weeks after the beginning of chemotherapy.
Patients were irradiated with megavoltage
photon beam (either GOCo teletherapy or 10 MV
photons). The clinical treatment volume
included the primary tumour with a 2-3 em
margin of normal tissue as visualised on the
RESULTS
chest CT scan, and regional lymph nodes. A
total dose of 44 - 45 Gy, in fractions of 1.8-2
Gy, was delivered to this large volume and
then a boost to the primary tumour of up to 54
-55 Gy was applied. In the case of lack of
complete regression of primary tumour, further
escalation of dose was possible. The overall
response was assessed four weeks after the
fifth course of chemotherapy. Restaging
examination included chest X-ray, chest CT if
needed, bronchoscopy with biopsy or brushing
of suspicious areas.
At the beginning, we did not use prophylactic
cranial irradiation (PCI) in our protocol. In May
1995, after our first analysis, because of the
high incidence of brain metastases in the initial
group of patients, the strategy was changed
and all patients with CR received 30 Gy PCI in
15 fractions.
Survival was calculated from the first day of
chemotherapy until treatment failure (death or
recurrence of the process), survivors being
censored at the date of their last control visit.
The Kaplan-Meier estimate was used to
calculate survival curves. The data were
processed using the Statistica program.
Characteristic
No of patients
Time of follow up
Sex
Age
Localisation
Time interval between the first
course of CHT and RT
No. of CHT courses
Total dose of RT
Overall treatment time
Female
Male
Right
Left
::; 30 days
> 30 days
5
4
3
2
Range (median) N(%)
32 (100)
4 - 34 (14) months
14 (43.8)
18 (56.2)
28 - 73 (49) years
18 (56.2)
14 (43.8)
5 - 114 (30) days
17 (53.1)
15 (46.9)
24 (75)
6 (18.8)
1 (3.1)
1 (3.1)
29.4 - 69.6 (55) Gy*
25 - 67 (45) days
*- 69.6 Gy was given to one patient, CHT - chemotherapy, RT - radiotherapy
Table 1. Clinical characteristics of 32 patients.
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NO Nl N2 N3
Tl 0 0 1 0 1
T2 3 0 6 0 9
T3 0 7 4 2 13
T4 1 0 5 3 9
Total 4 7 16 5 32
Table 2. Distribution of patients by TNM stage.
o Deattl or failure
Survival curves of patients with and without
PCI were compared using the log rank test.
The two-year actuarial survival rates were 35%
and 0% respectively, p=0.06 (Figure 2).
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Clinical characteristics of 32 patients treated
are presented in tables 1 and 2.· The time of
follow-up ranged from 4 to 34 months, median
14 months. Complete regression was obtained
in 22 of 30 patients (Le. 73.3%),.who received
at least 4 courses of EP chemotherapy and a
tumour dose of 50 Gy or more. Two patients
did not receive this therapy: one of them died
of pulmonary haemorrhage after the third
course of chemotherapy, and in another
patient we had to change the chemotherapy
regimen because of renal insufficiency after
the first course of EP. In the whole group of 32
patients, the 2-year actuarial disease-free
survival was 21 %. (Figure 1).
o DHlh or failure
Fig. 1. Actuarial disease-free survival in 32 patients with
SCLC treated in COK between 1994-98.
Fifteen patients are still alive, 11 with no
evidence of disease, two with incomplete
regression and two with distant metastases
after initial CR. Seventeen patients died, one
patient with CR, and one patient with partial
regression during treatment, due to of
pulmonary haemorrhage.
Brain metastases (BM) were found in 8
(36.4%) patients with CR, in 5fi (71.4%)
without PCI and in 3/15 (20%) with PCI.
0.0
o
Fig. 2. Comparison of survival rates in groups of patients
with and without PCI (only in CR).
To assess whether the delay in radiotherapy
could adversely influence survival, we
compared the survival time of chest irradiatied
patients treated with before and after one
month after the first course of chemotherapy,
using the Mann-Whitney U test. The mean
survival time was 15.5 vs. 9.5 months,
respectively. The difference was statistically
significant, P=0.025.
The early toxicity of concurrent
chemoradiotherapy was mild to moderate
(table 3). The most frequent side effect was
anaemia, and 34.4% of patients required blood
transfusion. Transient alopecia developed in all
patients. Severe oesophagitis was observed in
12.5% patients. PCI tolerance was good. Since
we routinely used antiemetics during
chemotherapy, nausea and vomiting did not
affect the schedule of treatment. Up to now we
have not observed any severe late effects.
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Trombocytopenia
76 - 100 x109/1 4 12.5
50 -75 x109/l 4 12.5
Leukopenia
2.51 - 3.0 x109/1 6 18.8
2.01 - 2.5 x109/1 4 12.5
1.01 - 2.0 x109/1 7 21.9
Infection (treated with antibiotics) 13 40.6
Anaemia
G 1* 15 46.9
G2 2 6.3
Transfusions 11 34.4
Oesophagitis
G 1-2 9 28.1
G3-4 2 12.5
Weight loss < 5% 7 21.9
Other: haemorrhage, stomach ulcer, renal 3 9.7
insufficiency
* - toxicity scale according to WHO.
Table 3. Toxicity in 32 patients treated with concurrent chemoradiotherapy.
DISCUSSION
The analysed group of patients treated is
small. Our patients had relatively more
advanced tumours than those treated at other
centres. According to the Manchester score
system, about 50% of our patients would have
scored two or above (Thatcher et aI., 1998).
This classification comprises the total
estimation of 6 parameters which influence the
prognosis (one item for each parameter): LDH
activity <450 Uti, extended disease (there are
some differences in the definition of Iimited-
stage disease), serum sodium level <132
mmoltl, performance status on the Karnofsky
scale, of below 60%, alkaline phosphatase
activity >165 Uti (1,5 times the x upper limit of
norm), bicarbonates >24 mmoltl. The best
prognosis is for values 0-1, moderate for 2-3,
and poor for 4 or more.
In the group of 32 patients the2-year
actuarial disease-free survival was 21 %. No
patient who survived longer than two years,
recurred.
The high incidence of brain metastases (8M)
caused a modification of our treatment
protocol. All patients treated before May 1995
died and 71.4% of them because of 8M. In the
literature, the value of PCI remains
controversial. The critical issues are the value
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of PCI, the optimum irradiation dose, and the
time interval between the treatment of the
primary tumour and the initiation of PCI ("early"
vs. "late" PCI). All large trials have shown a
consistent survival advantage in favour of the
PCI mode (Gregor et al., 1997; Le Chevalier
and Arriagada, 1997). Until now, no individual
sample size was large enough to statistically
confirm this survival benefit, but a meta-
analysis is in progress and will results are
expected soon (Gregor, 1998). In a group of
199 patients Work et aI., tested the hypothesis
that the benefit from PCI would be expected
mainly among the patients with the best
prognosis. In the group of patients with
favourable prognostic parameters, the survival
advantage from PCI was statistically
significant: the 3-year disease-free survival
was 35.5% in patients with PCI vs. 14.1 % in
patients without PCI, P=0.029 (Work et aI.,
1996). Our results indicate that patients in CR
could benefit from PCI (Figure-2).
In our study, due to logistic problems, the
interval between chemotherapy and chest
irradiation varied from 5 to 114 days (average
1 month). Extension of this interval over one
the month seems to have had a negative
influence on survival time. \
In 1993, Murray et al. reported that cisplatin-
etoposide chemotherapy in combination with
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radiotherapy beginning at cycle 2 of chemothe-
rapy was superior to concurrent radiotherapy
beginning at cycle 6.
Similar results were published by Jeremic et
al. in a randomised study on the optimal timing
of chest irradiation in combination with
concurrent chemotherapy in limited-stage
SCLC. One-hundred and seven patients were
enrolled in the stUdy. Patients who received
concurrent chemoradiation at weeks 1 to 4 had
a significantly higher local control and survival
rate. The five-year survival rate in these patients
was 30% compared with 15% in the group
irradiated at weeks 6 to 9 (Jeremie et aI., 1997).
Two other randomised studies addressing
the timing of chest irradiation in combination
with chemotherapy in limited-stage SCLC have
been reported. The Danish trial, presented by
Work et aI., showed that the timing of chest
irradiation had no impact on the outcome.
However, careful examination of the treatment
design for this trial shows that chest irradiation
was not administered concurrently with
chemotherapy in either arm (Work et al.,
19,97). The survival rates in this trial were
poorer in comparison with results presented by
those groups where early chest irradiation was
combined with concurrent chemotherapy (two-
year survival 19% and 20% vs. 40%).
The trial presented by EORTC Lung Cancer
Cooperative Group also failed to confirm the
superiority of an alternating (early) versus
sequential (late) schedule of delivery of chest
,irradiation. In this trial, five courses of CDE
chemotherapy followed by continuous chest
irradiation 50 Gy in 20 daily fractions (arm S)
were compared with the same total dose of
chemotherapy and irradiation split into four
courses of five daily fractions delivered on
days 14 to 21 of the second and subsequent
chemotherapy courses (arm A). For combination
of chemotherapy and radiotherapy in arm A,
haematological toxicity compromised treatment
delivery and could have contributed to the overall
results. The poorer rates of local control are
disappointing and require intensification of the
radiation therapy strategy (Gregor et aJ., 1997).
The latest data published by Turrisi et al.
suggest that twice-daily accelerated chest
radiotherapy has potential advantages over
once-daily radiotherapy. Four cycles of cisplatin
plus etoposide and a course of radiotherapy (45
Gy, given either once or twice daily) beginning
with the first cycle of chemotherapy, resulted in
overall 2- and 5-year survival rates of 44% and
23%, respectively. These results constitute a
considerable improvement in survival rates over
the previous results in patients with limited
stage SCLC, but the optimum manner of
delivering radiotherapy is yet to be defined.
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The tolerance of concurrent chemoradiation
in our study was good. Basing on our results
and on data from literature, we modified our
treatment protocol as follows: (1) all patients
with CR are routinely treated with PCI, (2) we
try to begin chest irradiation no later than two
weeks from the first day of chemotherapy and
(3) in treatment planning, we apply CT scans
to minimise treatment - related oesophagitis.
We also intensified our chemotherapy regimen
by adding ifosphamide to cisplatin and
etoposide.
CONCLUSIONS
1. In patients with complete remiSSion
prophylactic cranial irradiation (PCI)
reduces the incidence of brain metastases.
We found brain metastases in 5/7 (71,4%)
patients without PCI, and in 3/15 (20%)
patients after PCI.
2. Our results suggest that the timing of chest
irradiation may affect the outcome, but
observation of a larger group of patients is
required.
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